Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain

A technology of norepinephrine and reuptake inhibitors, applied in the field of serotonin and norepinephrine reuptake inhibitors, can solve the problems of treatment plans without SNRI and opioid agonist combination

Inactive Publication Date: 2015-04-22
THERAVANCE BIOPHARMA R&D IP LLC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Despite early indications and years of research utilizing combination therapy, there are no commonly used treatment options combining SNRIs and opioid agonists

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
  • Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
  • Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain

Examples

Experimental program
Comparison scheme
Effect test

example A

[0080] Formulation Example A: Hard Gelatin Capsule for Oral Administration

[0081] Compound 1 (20 mg), starch (89 mg), microcrystalline cellulose (89 mg) and magnesium stearate (2 mg) were blended well and then passed through a 45 mesh U.S. sieve. The resulting composition was loaded into hard gelatin capsules (200 mg composition / capsule).

example B

[0082] Formulation Example B: Hard Non-Gelatin (HPMC) Capsules for Oral Administration

[0083] Compound 1 (10 mg), polyoxyethylene sorbitan monooleate (50 mg) and starch powder (250 mg) were blended well and then loaded into hard non-gelatin (HPMC) capsules (310 mg composition / capsule).

example C

[0084] Formulation Example C: Tablet for Oral Administration

[0085] Compound 1 (5 mg), microcrystalline cellulose (400 mg), fumed silicon dioxide (10 mg) and stearic acid (5 mg) were blended thoroughly and then compressed to form tablets (420 mg composition / tablet).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method of treating a pain condition in a mammal utilizing a specific serotonin and norepinephrine reuptake inhibitor (SNRI) and also the combination of the SNRI and an opioid agonist agent. The invention includes methods wherein the opioid agonist agent is administered at a dose that is lower than a dose administered for treating a pain condition when used alone.

Description

technical field [0001] The present invention relates to the use of serotonin and norepinephrine reuptake inhibitors having specific properties for the treatment or management of pain, and to specific serotonin and norepinephrine reuptake inhibitors by themselves or in combination with opioid agonists Use in combination for the treatment or management of pain. Background technique [0002] Pain is an uncomfortable sensory and emotional experience related to or elucidated in terms of actual or potential tissue damage (International Association for the Study of Pain (IASP), Pain Terminology). For example, acute pain following surgery usually resolves when the underlying source of pain is removed or the wound has healed. Chronic pain lasts longer than acute pain or beyond the expected time for wound healing (American Pain Society. "Pain Control in the Primary Care Setting" 2006: 15). Neuropathic pain is pain initiated or caused by primary damage or dysfunction of the nervous s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/451A61K31/485A61P25/04A61P29/02A61K31/138A61K31/38A61K45/06
CPCA61K31/485A61K31/451A61K31/38A61K31/138A61K45/06A61P25/04A61P29/00A61P29/02A61P43/00A61K2300/00
Inventor 威廉·J·马丁沈菲杰奎琳·A.M.·史密斯
Owner THERAVANCE BIOPHARMA R&D IP LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com